Alzamend Neuro EBITDA vs. Shares Outstanding

ALZN Stock  USD 1.31  0.01  0.77%   
Considering Alzamend Neuro's profitability and operating efficiency indicators, Alzamend Neuro may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Alzamend Neuro's ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-9.9 M
Current Value
-10.4 M
Quarterly Volatility
3.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Alzamend Neuro's Average Payables is very stable compared to the past year. As of the 24th of November 2024, ROIC is likely to grow to 4.55, while PTB Ratio is likely to drop (1.95).
For Alzamend Neuro profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Alzamend Neuro to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Alzamend Neuro utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Alzamend Neuro's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Alzamend Neuro over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(142.87)
Return On Assets
(2.14)
Return On Equity
(44.08)
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Alzamend Neuro Shares Outstanding vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Alzamend Neuro's current stock value. Our valuation model uses many indicators to compare Alzamend Neuro value to that of its competitors to determine the firm's financial worth.
Alzamend Neuro is rated second in ebitda category among its peers. It is rated below average in shares outstanding category among its peers . Alzamend Neuro reported last year EBITDA of (9.89 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alzamend Neuro's earnings, one of the primary drivers of an investment's value.

Alzamend Shares Outstanding vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Alzamend Neuro

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(9.89 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Alzamend Neuro

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
4.48 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Alzamend Shares Outstanding Comparison

Alzamend Neuro is currently under evaluation in shares outstanding category among its peers.

Alzamend Neuro Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Alzamend Neuro, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Alzamend Neuro will eventually generate negative long term returns. The profitability progress is the general direction of Alzamend Neuro's change in net profit over the period of time. It can combine multiple indicators of Alzamend Neuro, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Loss-13.4 M-12.7 M
Net Interest Income-10.1 K-10.6 K
Operating Income-9.9 M-10.4 M
Net Loss-9.9 M-10.4 M
Income Before Tax-9.9 M-10.4 M
Total Other Income Expense Net-10.1 K-9.6 K
Net Loss-9.9 M-10.4 M
Income Tax Expense-166.6 K-158.2 K
Non Operating Income Net Other3.6 K3.4 K
Change To Netincome4.1 M2.5 M
Net Loss(14.72)(15.45)
Income Quality 0.83  0.81 
Net Income Per E B T 0.90  0.81 

Alzamend Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Alzamend Neuro. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Alzamend Neuro position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Alzamend Neuro's important profitability drivers and their relationship over time.

Use Alzamend Neuro in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.

Alzamend Neuro Pair Trading

Alzamend Neuro Pair Trading Analysis

The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Alzamend Neuro position

In addition to having Alzamend Neuro in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Heavy Metals Thematic Idea Now

Heavy Metals
Heavy Metals Theme
Companies involved in mining, production, and distribution of various industrial metals and minerals. The Heavy Metals theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Heavy Metals Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock:
Check out Trending Equities.
To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
To fully project Alzamend Neuro's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Alzamend Neuro at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Alzamend Neuro's income statement, its balance sheet, and the statement of cash flows.
Potential Alzamend Neuro investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Alzamend Neuro investors may work on each financial statement separately, they are all related. The changes in Alzamend Neuro's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alzamend Neuro's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.